Advaxis, Inc. To Participate In Canaccord Genuity Orphan Drug One-On-One Day
2/18/2014 9:09:09 AM
PRINCETON, N.J., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it will participate in the Canaccord Genuity Orphan Drug One-on-One Day, Monday, February 24, 2014 at the Omni Berkshire Place in New York.
Help employers find you! Check out all the jobs and post your resume.
comments powered by